Lexaria's Human GLP-1 Study #5 Begins Dosing
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide
Study will investigate Pharmacokinetics and Safety
KELOWNA, BC / ACCESS Newswire / April 2, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, is pleased to announce that dosing has begun as scheduled in its human study GLP-1-H25-5 (the 'Study') that is comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide.
On November 20, 2024, Lexaria reported on an earlier 12-week study in rodents which showed that with unlimited food available, oral DehydraTECH-liraglutide demonstrated a 5.88% weight reduction and an 11.54% blood sugar reduction as compared to baseline.
The current Study is designed to test pharmacokinetics ('PK') (absorption into bloodstream) and adverse events in humans. Lexaria has previously shown in other GLP-1 PK studies in humans, that certain oral DehydraTECH formulations demonstrated superior bloodstream delivery, as well as reduced adverse events as compared to the oral semaglutide and injectable tirzepatide products on the market today.
Liraglutide is currently sold only in an injectable form under the brand names Saxenda® and Victoza®, both manufactured by Novo Nordisk. Despite the launch of a genericized version of liraglutide by Teva Pharmaceutical Industries, Ltd. in June of 2024, Novo Nordisk generated US$1.0 billion in Saxenda® revenue, as well as an additional US$0.8 billion in Victoza® revenue during 2024.
Results of the Study will be released once available.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will,' and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Phone: 250-765-6424, ext 202
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Inside key meeting to remove Trump tariffs
Trade Minister Don Farrell has detailed the discussion he had with his US counterpart Jamieson Greer, revealing he had the 'greatest confidence' in Anthony Albanese during an expected meeting with Donald Trump next weekend. Senator Farrell spoke to the US Trade Representative while in Paris last week and characterised the talk as 'friendly'. Despite this, he maintained the tariffs were 'simply unjustified', highlighting Australia's trade surplus with the US. Figures indicate Australia buys about $70bn worth of goods from the US, compared to the $30bn of exports Australia sells to America. 'It wasn't a difficult discussion in terms of the relationship between us, and I am certainly of the view that we have the opportunity to continue to talk with Jamieson and Commerce Secretary Lutnick to put our case across,' he said. Senator Farrell also said he was still determined to get the trade barriers slashed. 'It's only by open discussion, honest discussion, with our allies in the United States that I think we can do that, but I certainly haven't given up on the prospect of getting these tariffs removed,' he said. 'And every opportunity I get, I'll continue to pursue that argument with the United States.' However, Senator Farrell said the decision will be ultimately made by Donald Trump, putting increased pressure on Mr Albanese's upcoming meeting with the US President. He said that while there were a 'range of ways' in which Australia communicates with the US, the 'most important … relationship between our prime minister and the president of the United States'. 'Look every meeting, I think, between an Australian Prime Minister and the US president will always be a critical meeting and I have the greatest confidence in our prime minister to push the Australian point of view on this.' The trade barriers currently include a 50 per cent levy on steel, a 25 per cent tariffs on aluminium and a blanket 10 per cent on other goods. While Mr Albanese maintained he won't compromise on Australia's biosecurity, he hinted Australia could review current settings which don't allow the US to import beef which originates from Canada and Mexico. Mr Albanese has also ruled out changes to the Pharmaceuticals Benefit Scheme, News Media Bargaining code and incoming ban on social media for under-16s, while highlighting Australia's critical minerals industry as a potential bargaining chip. 'If things can be sorted out in a way that protects our biosecurity – of course, we don't just say no, we don't want imports in here for the sake of it,' he told ABC radio on Friday. 'But our first priority is biosecurity and there'll be no compromise on that.' Mr Albanese said Australia would not have a 'subservient relationship to any nation'. 'We're a sovereign nation that stand on our own two feet,' he said. Senator Farrell also said he was 'confident' Australia can secure a new trade deal with the European Union, with EU President Ursula von der Leyen expected to visit Australia in July or August. 'We've got lots of things that we can sell to the to the Europeans. I believe now that there's an appetite to reach an agreement on both sides,' he said. 'The world has changed, those countries that believe in free and fair trade have to work together.'
Yahoo
3 hours ago
- Yahoo
'Haven't given up': minister seeks tariff breakthrough
Australia's trade minister remains confident tariffs imposed by the US will be removed, ahead of a likely meeting between Anthony Albanese and Donald Trump. The two leaders could meet on the sidelines of the G7 summit in Canada next week, with the economic measures imposed by the US president around the world set to dominate discussions. As Australia looks to negotiate for an exemption on tariffs, Trade Minister Don Farrrell was optimistic a deal could be reached. "I certainly haven't given up on the prospect of getting these tariffs removed, and every opportunity I get, I'll continue to pursue that argument with the United States," he told Sky News on Sunday. "There is no justification for the United States to impose tariffs on Australia ... we want all of the tariffs removed, not just some of them." Mr Trump recently signed off on doubling tariffs on exports on steel and aluminium from 25 to 50 per cent. All other Australian exports to the US have been slapped with a 10 per cent tariff. Senator Farrell met with US trade representative Jamieson Greer last week and said he pushed the case for all of the economic measures to be removed. The minister was hopeful a similar approach that removed $20 billion worth of tariffs on Australian goods entering China could be used with America. "We didn't retaliate on that occasion, and bit by bit, we managed to get all of those tariffs that had been applied on Australia by China removed. I'd like to do the same with the United States," he said. "It's only by open discussion, honest discussion with out allies in the United States that I think we can do that." As the US Defence Secretary Pete Hegseth urged Australia to increase its defence spending by billions of dollars to 3.5 per cent of GDP, Senator Farrell said the federal government had already proved its commitment through the AUKUS submarine deal. Australia is looking to up its total spent on defence to 2.3 per cent. "We are committed to the defence of this country, we are committed to a significant uplift in the amount of spending," Senator Farrell said. "(AUKUS) is going to be a project that's worth more than $360 billion, so I think we've talked the talk." Prime Minister Anthony Albanese signalled on Friday negotiations on opening up access to US beef into Australia could be on the table as part of tariff negotiations. However, he said biosecurity would not be compromised in order to reach an agreement.
Yahoo
9 hours ago
- Yahoo
Amazon.com (NasdaqGS:AMZN) Expands AWS Presence With US$5 Billion Data Center Investment In Taiwan
recently announced the launch of its AWS Asia Pacific (Taipei) Region, highlighting a $5 billion investment in data center infrastructure. This expansion, coupled with a $10 billion investment in North Carolina to bolster AI and cloud computing capabilities, underscores Amazon's commitment to innovation and business growth. These significant developments align with Amazon's overall strategic objectives and may enhance its market position. The company's share price rose 13% over the past month, coinciding with the market's general upward trend, which experienced a 13% rise over the past year across the broader market. Buy, Hold or Sell View our complete analysis and fair value estimate and you decide. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent developments regarding Amazon's investments in the AWS Asia Pacific (Taipei) Region and North Carolina can significantly influence the company's operational strategy, furthering its drive towards AI and cloud computing capabilities. These initiatives are expected to enhance revenue streams, aligning with the company's narrative of optimizing efficiency through advanced technologies. Over the three-year timeframe, Amazon's total shareholder return, inclusive of share price and dividends, achieved a 94.77% increase. Within the past year, Amazon's share price rise of 13% outpaced the broader market's 12.6% gain, reflecting robust performance despite prevailing industry challenges. In light of Amazon's stated commitments, analysts have projected revenue growth of 8.9% per annum, bolstered by both traditional and AI-driven cloud services. Earnings prospects are anticipated to rise to US$103.6 billion by 2028, up from US$65.94 billion today. While these expansions present opportunities for substantial revenue increases, the pressure from infrastructure investments must be carefully managed to sustain growth expectations. With a current share price of US$185.01, the 22.7% higher analyst price target of US$239.33 illustrates an optimistic market consensus. However, investors are advised to consider both market risks and the variations in analyst predictions when evaluating Amazon's future prospects. Unlock comprehensive insights into our analysis of stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:AMZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
